Type 1.5 diabetes also known as latent autoimmune diabetes in adults (LADA) is an important form of diabetes which occurs in about 10% of patients classified as type 2 diabetes and not initially requiring insulin. β- cell dysfunction in type 1.5 diabetes is caused mainly by Glutamic acid decarboxylase antibody (GADA). β- cell stress results in an induction of Heat shock protein 90 (Hsp90) expression, where Hsp 90 is a regulator of Class II antigen processing and presentation. In silico docking studies and drug likeliness analysis have shown that docking target protein Hsp 90 α with the ligand mangiferin had a protective role against autoimmune destruction. This study paves way for treating the autoimmune diabetes at the immunity level.